Trial Profile

A Randomized, Placebo-Controlled, Double-Blinded Trial of the Safety and Efficacy of Tecovirimat for the Treatment of Human Mpox Virus Disease

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 24 Apr 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tecovirimat (Primary)
Indications Monkeypox
Focus Therapeutic Use
Acronyms STOMP

Most Recent Events

27 Mar 2026 According to a European Medicines Agency media release, , CHMP, has recommended that Tecovirimat SIGA should no longer be used for the treatment of mpox followed by the review of data from four studies PALM007, STOMP, UNITY and PLATINUM-UK.
10 Feb 2026 Status changed from active, no longer recruiting to discontinued, due to statistical futility.
12 Mar 2025 Results presented in the ACTG Media Release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com